Cycle Pharmaceuticals Ltd press office | hosted by Press Dispensary

Cycle Pharmaceuticals Ltd logo - click for high-res version


Press releases

Les comprimés Nitisinone de Cycle Pharmaceuticals deviennent le premier traitement de la tyrosinémie héréditaire de type 1 (TH-1) à passer avec succès la rigoureuse évaluation de l'INESSS en répondant à tous les critères de valeur thérapeutique.

INESSS makes first ever recommendation for HT-1 treatment
Les comprimés Nitisinone de Cycle Pharmaceuticals deviennent le premier traitement de la tyrosinémie héréditaire de type 1 (TH-1) à passer avec succès la rigoureuse évaluation de l'INESSS en répondant...
More ...


Cycle Pharmaceutical's Nitisinone Tablets becomes first HT-1 treatment to pass through INESSS' rigorous evaluation satisfying all therapeutic value criteria.

INESSS makes first ever recommendation for HT-1 treatment
Patients in Quebec with the rare, life-threatening disease HT-1 received a boost today with the announcement that INESSS is making its first ever recommendation for an HT-1 treatment, Nitisinone Table...
More ...


CYCLE Pharmaceuticals, the University of Cambridge and King's College London partner to repurpose PARP inhibitor drugs for vascular disease

Professor Melinda Duer, U of Cambridge
Cambridge Enterprise (University of Cambridge) has exclusively licensed, to CYCLE Pharmaceuticals, intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease.
More ...


Los comprimidos de nitisinona de Cycle Pharmaceuticals fueron aprobados por Health Canada (ministerio de salud de Canadá) para el tratamiento de la tirosinemia hereditaria tipo I.

Los comprimidos de nitisinona de Cycle Pharmaceuticals
Los comprimidos de nitisinona de Cycle Pharmaceuticals fueron aprobados por Health Canada (ministerio de salud de Canadá) para el tratamiento de la tirosinemia hereditaria tipo I.
More ...


Comprimidos de nitisinona da Cycle Pharmaceuticals são aprovados pelo Departamento de Saúde Pública do Canadá (Health Canada) no tratamento da Tirosinemia Hereditária Tipo 1

Comprimidos de nitisinona da Cycle Pharmaceuticals
Comprimidos de nitisinona da Cycle Pharmaceuticals são aprovados pelo Departamento de Saúde Pública do Canadá (Health Canada) no tratamento da Tirosinemia Hereditária Tipo 1...
More ...


Nitisinon-Produkt von Cycle Pharmaceuticals von Health Canada für die Behandlung von erblicher Tyrosinämie Typ 1 zugelassen

Nitisinon-Produkt von Cycle Pharmaceuticals
Nitisinon-Produkt von Cycle Pharmaceuticals von Health Canada für die Behandlung von erblicher Tyrosinämie Typ 1 zugelassen...
More ...


أقراص نيتيسينون من شركة Cycle Pharmaceuticals المُعتمدة من هيلث كندا لعلاج مرض فرط
تيروزين الدم الوراثي نمط 1 (Tyrosinemia Type 1).

أقراص نيتيسينون من شركة Cycle Pharmaceuticals المُع...
More ...


Approbation par Santé Canada des comprimés de nitisinone fabriqués par Cycle Pharmaceuticals pour le traitement de la tyrosinémie héréditaire de type 1

Approbation par Santé Canada des comprimés de nitisinone fabriqués par Cycle Pharmaceuticals pour le traitement de la tyrosinémie héréditaire de type 1
Approbation par Santé Canada des comprimés de nitisinone fabriqués par Cycle Pharmaceuticals pour le traitement de la tyrosinémie héréditaire de type 1...
More ...


Cycle Pharmaceuticals Nitisinone Tablets approved by Health Canada for the treatment of Hereditary Tyrosinemia Type 1.

INESSS makes first ever recommendation for HT-1 treatment
Cycle Pharmaceuticals Nitisinone Tablets approved by Health Canada for the treatment of Hereditary Tyrosinemia Type 1.
More ...



About Cycle Pharmaceuticals Ltd

Pharmaceutical drug development

Cycle Pharmaceuticals is a Cambridge-based pharmaceutical company that optimises and increases access to existing pharmaceuticals. Specifically, Cycle focuses on three areas of pharmaceutical development:
• Improving orphan drugs, which treat the under-served rare disease patient community;
• Reinstating drug products that have been previously marketed;
• Working with our academic and other partners to extend pharmaceuticals to new medical areas where there is unmet need.
For further information on Cycle Pharmaceuticals, please visit http://www.cyclepharma.com.

For more information

Cycle Pharmaceuticals Ltd

Sonya Gade
project manager
Phone: + 44 (0) 1223 803 644
Email: sonya.gade@cyclepharma.com
Site: www.cyclepharma.com

RSS newsfeed:
http://www.pressdispensary.co.uk/
rssfeed/q991918/rss.xml